article Open AccessTop 1% cited
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2012 · Vol. 23 · pp. vii56–vii64
Solange Peters(University Hospital of Lausanne)Alex A. Adjei(Roswell Park Comprehensive Cancer Center)Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati)Martin Reck(LungenClinic Grosshansdorf)K.M. Kerr(Aberdeen Royal Infirmary)Enriqueta Felip✉(University Hospital of Lausanne)
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Diagnosis and TreatmentMedicineOncologyLung cancerClinical PracticeCancerInternal medicineFamily medicine
MeSH terms
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCombined Modality TherapyHumansLung NeoplasmsNeoplasm StagingPalliative CareRandomized Controlled Trials as TopicTreatment OutcomeRisk AssessmentMolecular Targeted TherapyMaintenance Chemotherapy
Citations
928
FWCI
77.64
field-weighted impact
References
91
Percentile
100%
vs. same field & year
Citations per year
Cited by
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,299 citations
References
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2008 · 3,206 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
The Lancet Oncology · 2012 · 5,500 citations
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Journal of Clinical Oncology · 2000 · 2,183 citations
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Journal of Clinical Oncology · 2004 · 2,425 citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
Journal of Clinical Oncology · 2009 · 1,873 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.